1. Home
  2. TG vs CRNX Comparison

TG vs CRNX Comparison

Compare TG & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tredegar Corporation

TG

Tredegar Corporation

HOLD

Current Price

$8.28

Market Cap

353.3M

Sector

Industrials

ML Signal

HOLD

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$37.88

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TG
CRNX
Founded
1988
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
353.3M
3.9B
IPO Year
1994
2018

Fundamental Metrics

Financial Performance
Metric
TG
CRNX
Price
$8.28
$37.88
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$76.75
AVG Volume (30 Days)
172.2K
1.3M
Earning Date
05-08-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
151.06
N/A
EPS
0.17
N/A
Revenue
$800,821,000.00
$1,039,000.00
Revenue This Year
N/A
$720.10
Revenue Next Year
N/A
$184.67
P/E Ratio
$48.24
N/A
Revenue Growth
8.29
N/A
52 Week Low
$6.25
$25.83
52 Week High
$10.53
$57.99

Technical Indicators

Market Signals
Indicator
TG
CRNX
Relative Strength Index (RSI) 38.23 46.14
Support Level $7.30 $33.19
Resistance Level $9.03 $43.71
Average True Range (ATR) 0.60 2.28
MACD -0.21 -0.30
Stochastic Oscillator 9.88 27.73

Price Performance

Historical Comparison
TG
CRNX

About TG Tredegar Corporation

Tredegar Corp is engaged in the manufacture of aluminum extrusions and polyethylene and polypropylene plastic films. It produces surface protection films, packaging films and films for other markets. The company continues to have two reportable segments: Aluminum Extrusions and High Performance Films. The majority of the revenue is derived form the Aluminum Extrusions segment which produces high-quality, soft and medium strength alloyed aluminum extrusions, custom fabricated and finished, for the building and construction, automotive and transportation, consumer durables goods, machinery and equipment, electrical and renewable energy, and distribution markets.

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

Share on Social Networks: